Please assess the completion status of the following clinical trial:

Trial Title: Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of dementia of the Alzheimer type (DSM-IV Text Revision (TR) criteria)~2. Mini-mental state examination (MMSE) \>18, but \<29~3. Apathy Evaluation Scale (AES) score of more than 40~4. Ability to provide informed consent by either the patient or caregiver.~5. If subjects are being treated with antidepressants, they should be on a stable dose of antidepressants for at least two months prior to the enrollment into the study.~6. If subjects are being treated with cholinesterase inhibitors and memantine, they should be on stable dose of those medications at least four months prior to the enrollment into the study.~Exclusion Criteria:~1. Patient currently taking methylphenidate or hypersensitivity or prior significant adverse events with methylphenidate.~2. Patients currently taking Adderall (amphetamine mixed salts) or Dexedrine (dextroamphetamine sulphate) or any other amphetamine product.~3. Uncontrolled hypertension (BP \> 140/90) or tachycardia (100) at screening visit~4. Patients with frontotemporal dementia~5. Patients meeting criteria for Major Depressive Disorder on the Mini International Neuropsychiatric Inventory (MINI)~6. Patients with active psychosis as determined by MINI~7. Patients currently being treated with antipsychotics~8. History of uncontrolled seizure disorder~9. History of malignant hypertension, symptomatic cardiovascular disease, cardiomyopathy, known structural cardiac defect or medically unstable arrhythmias.~10. History of Tourette's syndrome or presence of motor tics~11. Patients with glaucoma~12. Patients taking monoamine oxidase inhibitors (MAOIs)~13. Patient taking clonidine

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Methylphenidate
- Arm 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).